A retrospective multicenter study of carbon-ion radiotherapy for external auditory canal and middle ear carcinomas

Kazuhiko Hayashi, Masashi Koto, Yusuke Demizu, Jun ichi Saitoh, Hiroaki Suefuji, Tomoaki Okimoto, Tatsuya Ohno, Yoshiyuki Shioyama, Ryo Takagi, Hiroaki Ikawa, Kenji Nemoto, Takashi Nakano, Tadashi Kamada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: We conducted a retrospective multicenter study to assess the clinical outcomes of carbon-ion radiotherapy (CIRT) for head and neck malignancies (Japan Carbon-Ion Radiation Oncology Study Group [J-CROS] study: 1402 HN). We aimed to evaluate the safety and efficacy of CIRT in patients with external auditory canal (EAC) and middle ear (ME) carcinomas. Methods: Thirty-one patients treated with CIRT at four Japanese institutions were analyzed. Fourteen patients (45.2%) had squamous cell carcinomas, 13 (41.9%) had adenoid cystic carcinomas, and four (12.9%) had other types. Nineteen (61.3%), six (19.4%), three (9.7%), and three (9.7%) patients had T4, T3, T2, and T1 disease, respectively. All patients had N0M0 status. The median radiation dose was 64 Gy (relative biological effectiveness) in 16 fractions. The median gross tumor volume was 33.3 mL. Results: The median follow-up period was 18.4 months (range, 5.1-85.6). The 1- and 3-year local control and overall survival rates were 75.0% and 55.0% and 79.3% and 58.7%, respectively. Regarding grade 3 or higher toxicities, three patients (9.7%) had grade 3 dermatitis, one (3.2%) had grade 3 mucositis, and two (6.5%) had grade 3 central nervous necrosis (ie, radiation-induced brain necrosis). No grade 4 or worse reactions were observed. Conclusion: CIRT was effective for EAC and ME carcinomas.

Original languageEnglish
Pages (from-to)51-57
Number of pages7
JournalCancer Medicine
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 2019

Fingerprint

Heavy Ion Radiotherapy
Ear Canal
Middle Ear
Multicenter Studies
Retrospective Studies
Carcinoma
Necrosis
Relative Biological Effectiveness
Radiation
Adenoid Cystic Carcinoma
Mucositis
Radiation Oncology
Dermatitis
Tumor Burden
Squamous Cell Carcinoma
Japan
Neck
Carbon
Survival Rate
Head

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Hayashi, K., Koto, M., Demizu, Y., Saitoh, J. I., Suefuji, H., Okimoto, T., ... Kamada, T. (2019). A retrospective multicenter study of carbon-ion radiotherapy for external auditory canal and middle ear carcinomas. Cancer Medicine, 8(1), 51-57. https://doi.org/10.1002/cam4.1830

A retrospective multicenter study of carbon-ion radiotherapy for external auditory canal and middle ear carcinomas. / Hayashi, Kazuhiko; Koto, Masashi; Demizu, Yusuke; Saitoh, Jun ichi; Suefuji, Hiroaki; Okimoto, Tomoaki; Ohno, Tatsuya; Shioyama, Yoshiyuki; Takagi, Ryo; Ikawa, Hiroaki; Nemoto, Kenji; Nakano, Takashi; Kamada, Tadashi.

In: Cancer Medicine, Vol. 8, No. 1, 01.2019, p. 51-57.

Research output: Contribution to journalArticle

Hayashi, K, Koto, M, Demizu, Y, Saitoh, JI, Suefuji, H, Okimoto, T, Ohno, T, Shioyama, Y, Takagi, R, Ikawa, H, Nemoto, K, Nakano, T & Kamada, T 2019, 'A retrospective multicenter study of carbon-ion radiotherapy for external auditory canal and middle ear carcinomas', Cancer Medicine, vol. 8, no. 1, pp. 51-57. https://doi.org/10.1002/cam4.1830
Hayashi, Kazuhiko ; Koto, Masashi ; Demizu, Yusuke ; Saitoh, Jun ichi ; Suefuji, Hiroaki ; Okimoto, Tomoaki ; Ohno, Tatsuya ; Shioyama, Yoshiyuki ; Takagi, Ryo ; Ikawa, Hiroaki ; Nemoto, Kenji ; Nakano, Takashi ; Kamada, Tadashi. / A retrospective multicenter study of carbon-ion radiotherapy for external auditory canal and middle ear carcinomas. In: Cancer Medicine. 2019 ; Vol. 8, No. 1. pp. 51-57.
@article{9e70cb5999064e7d95954b5365a989e5,
title = "A retrospective multicenter study of carbon-ion radiotherapy for external auditory canal and middle ear carcinomas",
abstract = "Background: We conducted a retrospective multicenter study to assess the clinical outcomes of carbon-ion radiotherapy (CIRT) for head and neck malignancies (Japan Carbon-Ion Radiation Oncology Study Group [J-CROS] study: 1402 HN). We aimed to evaluate the safety and efficacy of CIRT in patients with external auditory canal (EAC) and middle ear (ME) carcinomas. Methods: Thirty-one patients treated with CIRT at four Japanese institutions were analyzed. Fourteen patients (45.2{\%}) had squamous cell carcinomas, 13 (41.9{\%}) had adenoid cystic carcinomas, and four (12.9{\%}) had other types. Nineteen (61.3{\%}), six (19.4{\%}), three (9.7{\%}), and three (9.7{\%}) patients had T4, T3, T2, and T1 disease, respectively. All patients had N0M0 status. The median radiation dose was 64 Gy (relative biological effectiveness) in 16 fractions. The median gross tumor volume was 33.3 mL. Results: The median follow-up period was 18.4 months (range, 5.1-85.6). The 1- and 3-year local control and overall survival rates were 75.0{\%} and 55.0{\%} and 79.3{\%} and 58.7{\%}, respectively. Regarding grade 3 or higher toxicities, three patients (9.7{\%}) had grade 3 dermatitis, one (3.2{\%}) had grade 3 mucositis, and two (6.5{\%}) had grade 3 central nervous necrosis (ie, radiation-induced brain necrosis). No grade 4 or worse reactions were observed. Conclusion: CIRT was effective for EAC and ME carcinomas.",
author = "Kazuhiko Hayashi and Masashi Koto and Yusuke Demizu and Saitoh, {Jun ichi} and Hiroaki Suefuji and Tomoaki Okimoto and Tatsuya Ohno and Yoshiyuki Shioyama and Ryo Takagi and Hiroaki Ikawa and Kenji Nemoto and Takashi Nakano and Tadashi Kamada",
year = "2019",
month = "1",
doi = "10.1002/cam4.1830",
language = "English",
volume = "8",
pages = "51--57",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - A retrospective multicenter study of carbon-ion radiotherapy for external auditory canal and middle ear carcinomas

AU - Hayashi, Kazuhiko

AU - Koto, Masashi

AU - Demizu, Yusuke

AU - Saitoh, Jun ichi

AU - Suefuji, Hiroaki

AU - Okimoto, Tomoaki

AU - Ohno, Tatsuya

AU - Shioyama, Yoshiyuki

AU - Takagi, Ryo

AU - Ikawa, Hiroaki

AU - Nemoto, Kenji

AU - Nakano, Takashi

AU - Kamada, Tadashi

PY - 2019/1

Y1 - 2019/1

N2 - Background: We conducted a retrospective multicenter study to assess the clinical outcomes of carbon-ion radiotherapy (CIRT) for head and neck malignancies (Japan Carbon-Ion Radiation Oncology Study Group [J-CROS] study: 1402 HN). We aimed to evaluate the safety and efficacy of CIRT in patients with external auditory canal (EAC) and middle ear (ME) carcinomas. Methods: Thirty-one patients treated with CIRT at four Japanese institutions were analyzed. Fourteen patients (45.2%) had squamous cell carcinomas, 13 (41.9%) had adenoid cystic carcinomas, and four (12.9%) had other types. Nineteen (61.3%), six (19.4%), three (9.7%), and three (9.7%) patients had T4, T3, T2, and T1 disease, respectively. All patients had N0M0 status. The median radiation dose was 64 Gy (relative biological effectiveness) in 16 fractions. The median gross tumor volume was 33.3 mL. Results: The median follow-up period was 18.4 months (range, 5.1-85.6). The 1- and 3-year local control and overall survival rates were 75.0% and 55.0% and 79.3% and 58.7%, respectively. Regarding grade 3 or higher toxicities, three patients (9.7%) had grade 3 dermatitis, one (3.2%) had grade 3 mucositis, and two (6.5%) had grade 3 central nervous necrosis (ie, radiation-induced brain necrosis). No grade 4 or worse reactions were observed. Conclusion: CIRT was effective for EAC and ME carcinomas.

AB - Background: We conducted a retrospective multicenter study to assess the clinical outcomes of carbon-ion radiotherapy (CIRT) for head and neck malignancies (Japan Carbon-Ion Radiation Oncology Study Group [J-CROS] study: 1402 HN). We aimed to evaluate the safety and efficacy of CIRT in patients with external auditory canal (EAC) and middle ear (ME) carcinomas. Methods: Thirty-one patients treated with CIRT at four Japanese institutions were analyzed. Fourteen patients (45.2%) had squamous cell carcinomas, 13 (41.9%) had adenoid cystic carcinomas, and four (12.9%) had other types. Nineteen (61.3%), six (19.4%), three (9.7%), and three (9.7%) patients had T4, T3, T2, and T1 disease, respectively. All patients had N0M0 status. The median radiation dose was 64 Gy (relative biological effectiveness) in 16 fractions. The median gross tumor volume was 33.3 mL. Results: The median follow-up period was 18.4 months (range, 5.1-85.6). The 1- and 3-year local control and overall survival rates were 75.0% and 55.0% and 79.3% and 58.7%, respectively. Regarding grade 3 or higher toxicities, three patients (9.7%) had grade 3 dermatitis, one (3.2%) had grade 3 mucositis, and two (6.5%) had grade 3 central nervous necrosis (ie, radiation-induced brain necrosis). No grade 4 or worse reactions were observed. Conclusion: CIRT was effective for EAC and ME carcinomas.

UR - http://www.scopus.com/inward/record.url?scp=85058031516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058031516&partnerID=8YFLogxK

U2 - 10.1002/cam4.1830

DO - 10.1002/cam4.1830

M3 - Article

C2 - 30548207

AN - SCOPUS:85058031516

VL - 8

SP - 51

EP - 57

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 1

ER -